arrow
K

Karlijn de Joode

University Medical Center
H指数:9
被引数:522

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors

老年功能损伤对单药免疫疗法在实体瘤中疗效的影响

2025-10-040
OAAI
Response to letter Re: Impact of Immune-Related Adverse Events on Quality of Life and Physical Functioning in Older Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

回复信函:关于接受免疫检查点抑制剂治疗的老年实体瘤患者中,免疫相关不良事件对生活质量及躯体功能影响的问题

2025-09-220
PRE
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors

免疫相关不良事件对接受免疫检查点抑制剂治疗的老年实体瘤患者生活质量及躯体功能的影响

2025-06-070
OA
Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

SAFE STOP IPI-NIVO试验:在不可切除的III期或转移性黑色素瘤患者接受一线伊匹木单抗-纳武利尤单抗治疗后,若达到完全或部分缓解则早期停用纳武利尤单抗。

2024-09-010
PRE
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol
2024-05-232
OAAI
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

多组学分析将低白蛋白血症确定为转移性黑色素瘤PD-1阻断后不良预后的独立生物标志物

2024-05-164
OAAI
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma
2024-02-060
PRE
Original Research Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
2022-10-0110
OAAI